Antiparkinson drug (project company Rionis, LLC)
(Trade name – Prottremin®)
Prottremin® is an innovative drug for treating Parkinson’s disease (based on “DIOL” small molecule). Developed jointly with N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry.
Prottremin would enable a new therapeutic strategy for treating Parkinson’s disease based on neuroprotection and neuroregeneration, and not on dopamine substitution (which is the currently used tratment).
Unlike the known anti-Parkinson drugs, Prottremin normalizes dopamine production in the brain and activates the intracellular signal pathway MAPK, which control metabolism, proliferation, survival and regeneration of neurons.
Patent profile: patented in Russia, EAPO, USA, EU.
Indications for use:
– monotherapy in patients with early-stage Parkinson’s disease to halt progression and achieve disease regression without prescribing levodopa;
– combined therapy in patients with Parkinson’s disease (in combination with dopamine receptor agonists or levodopa) to halt progression and achieve disease regression as well as prolong the “efficacy window” of levodopa by reducing its dose in combined therapy;
– correction of extrapyramidal disorders in drug-induced parkinsonism (when antipsychotics are administered in patients with endogenous psychosis and age-related cognitive impairment).
Main advantages:
– alleviates the symptoms, being as potent as levodopa (the most effective anti-Parkinson drug);
– protects neurons from damage (neuroprotection), unlike the existing drugs;
– the first anti-Parkinson drug that restores damaged dopaminergic neurons (neuroregeneration);
– the first drug that not only treats the symptoms but also stops the progression of Parkinson’s disease;
– doesn’t cause the most severe adverse effects, inherent in levodopa – movement disorders (dyskinesia and fluctuations);
Current status: Substance and dosage form are developed. Pilot batches for preclinical and clinical studies are produced. Preclinical studies have been completed. Phase Ia and Ib clinical trials (in healthy volunteers) have finished successfully. Permission of the Ministry of Health of the Russian Federation for Phase II clinical trials (in patients with drug-induced parkinsonism) has been granted. Phase II clinical trials in patients with Parkinson’s disease are being prepared.
Video: https://youtu.be/Eql2jMmNCw8